BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 24098586)

  • 1. Effect of immune reconstitution on the incidence of HIV-related Hodgkin lymphoma.
    Kowalkowski MA; Mims MP; Amiran ES; Lulla P; Chiao EY
    PLoS One; 2013; 8(10):e77409. PubMed ID: 24098586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longer duration of combination antiretroviral therapy reduces the risk of Hodgkin lymphoma: A cohort study of HIV-infected male veterans.
    Kowalkowski MA; Mims MA; Day RS; Du XL; Chan W; Chiao EY
    Cancer Epidemiol; 2014 Aug; 38(4):386-92. PubMed ID: 24947588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy.
    Lanoy E; Rosenberg PS; Fily F; Lascaux AS; Martinez V; Partisani M; Poizot-Martin I; Rouveix E; Engels EA; Costagliola D; Goedert JJ;
    Blood; 2011 Jul; 118(1):44-9. PubMed ID: 21551234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics, incidence, and risk factors of HIV-related Hodgkin lymphoma in the era of combination antiretroviral therapy.
    Gotti D; Danesi M; Calabresi A; Ferraresi A; Albini L; Donato F; Castelli F; Scalzini A; Quiros-Roldan E;
    AIDS Patient Care STDS; 2013 May; 27(5):259-65. PubMed ID: 23600703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma.
    Shepherd L; Ryom L; Law M; Hatleberg CI; de Wit S; Monforte AD; Battegay M; Phillips A; Bonnet F; Reiss P; Pradier C; Grulich A; Sabin C; Lundgren J; Mocroft A
    J Natl Cancer Inst; 2018 Jun; 110(6):598-607. PubMed ID: 29267895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4⁺ T-cell lymphocytes.
    Bohlius J; Schmidlin K; Boué F; Fätkenheuer G; May M; Caro-Murillo AM; Mocroft A; Bonnet F; Clifford G; Paparizos V; Miro JM; Obel N; Prins M; Chêne G; Egger M;
    Blood; 2011 Jun; 117(23):6100-8. PubMed ID: 21368291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.
    del Amo J; Moreno S; Bucher HC; Furrer H; Logan R; Sterne J; Pérez-Hoyos S; Jarrín I; Phillips A; Lodi S; van Sighem A; de Wolf W; Sabin C; Bansi L; Justice A; Goulet J; Miró JM; Ferrer E; Meyer L; Seng R; Toulomi G; Gargalianos P; Costagliola D; Abgrall S; Hernán MA;
    Clin Infect Dis; 2012 May; 54(9):1364-72. PubMed ID: 22460971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A declining CD4 count and diagnosis of HIV-associated Hodgkin lymphoma: do prior clinical symptoms and laboratory abnormalities aid diagnosis?
    Gupta RK; Marks M; Edwards SG; Smith K; Fletcher K; Lee SM; Ramsay A; Copas AJ; Miller RF
    PLoS One; 2014; 9(2):e87442. PubMed ID: 24504076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid CD4 decline prior to antiretroviral therapy predicts subsequent failure to reconstitute despite HIV viral suppression.
    Darraj M; Shafer LA; Chan S; Kasper K; Keynan Y
    J Infect Public Health; 2018; 11(2):265-269. PubMed ID: 28826735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of boosted protease inhibitors reduces Kaposi sarcoma incidence among male veterans with HIV infection.
    Kowalkowski MA; Kramer JR; Richardson PR; Suteria I; Chiao EY
    Clin Infect Dis; 2015 May; 60(9):1405-14. PubMed ID: 25586682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study.
    Guiguet M; Boué F; Cadranel J; Lang JM; Rosenthal E; Costagliola D;
    Lancet Oncol; 2009 Dec; 10(12):1152-9. PubMed ID: 19818686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of HIV viral control on the incidence of HIV-associated anal cancer.
    Chiao EY; Hartman CM; El-Serag HB; Giordano TP
    J Acquir Immune Defic Syndr; 2013 Aug; 63(5):631-8. PubMed ID: 23614995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
    ; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
    Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination antiretroviral therapy with raltegravir leads to rapid immunologic reconstitution in treatment-naive patients with chronic HIV infection.
    Pallikkuth S; Fischl MA; Pahwa S
    J Infect Dis; 2013 Nov; 208(10):1613-23. PubMed ID: 23922374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological recovery failure in cART-treated HIV-positive patients is associated with reduced thymic output and RTE CD4+ T cell death by pyroptosis.
    Carvalho-Silva WHV; Andrade-Santos JL; Souto FO; Coelho AVC; Crovella S; Guimarães RL
    J Leukoc Biol; 2020 Jan; 107(1):85-94. PubMed ID: 31691351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent trends in early stage response to combination antiretroviral therapy in Australia.
    McManus H; Hoy JF; Woolley I; Boyd MA; Kelly MD; Mulhall B; Roth NJ; Petoumenos K; Law MG;
    Antivir Ther; 2015; 20(2):131-9. PubMed ID: 24704818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of lymphoma in HIV-HCV-infected patients. Modifications in function of the anti-hepatitis C virus therapy.
    Gutiérrez-Saborido D; Gutiérrez-Valencia A; González Domenech CM; López Ruz MÁ; Raffo Márquez M; Omar M; Girón-González JA;
    Ann Hematol; 2019 Aug; 98(8):1953-1959. PubMed ID: 31025161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of polymorphisms in the HCP5 and HLA-C, and ZNRD1 genes on HIV viral load.
    Thørner LW; Erikstrup C; Harritshøj LH; Larsen MH; Kronborg G; Pedersen C; Larsen CS; Pedersen G; Gerstoft J; Obel N; Ullum H
    Infect Genet Evol; 2016 Jul; 41():185-190. PubMed ID: 27083073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid suppression of HIV-RNA is associated with improved control of immune activation in Mozambican adults initiating antiretroviral therapy with low CD4 counts.
    Almeida JM; Letang E; Nhampossa T; Ayala E; David C; Menendez C; Gascon J; Alonso P; Naniche D
    AIDS Res Hum Retroviruses; 2011 Jul; 27(7):705-11. PubMed ID: 21091388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of effect of menopause status at initiation of first-line antiretroviral therapy on immunologic or virologic responses: a cohort study from Rio de Janeiro, Brazil.
    Calvet GA; Velasque L; Luz PM; Cardoso SW; Derrico M; Moreira RI; de Andrade AC; Cytryn A; Pires E; Veloso VG; Grinsztejn B; Friedman RK
    PLoS One; 2014; 9(2):e89299. PubMed ID: 24586673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.